BR112015023205A2 - composições e métodos para formulações de alfavírus vivo atenuado - Google Patents

composições e métodos para formulações de alfavírus vivo atenuado

Info

Publication number
BR112015023205A2
BR112015023205A2 BR112015023205A BR112015023205A BR112015023205A2 BR 112015023205 A2 BR112015023205 A2 BR 112015023205A2 BR 112015023205 A BR112015023205 A BR 112015023205A BR 112015023205 A BR112015023205 A BR 112015023205A BR 112015023205 A2 BR112015023205 A2 BR 112015023205A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
attenuated live
alphavirus
attenuated
Prior art date
Application number
BR112015023205A
Other languages
English (en)
Inventor
T Stinchcomb Dan
A Livengood Jill
Varga Laszlo
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023205(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of BR112015023205A2 publication Critical patent/BR112015023205A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo composições e métodos para formulações de alfavírus vivo atenuado as presentes modalidades referem-se ao campo de composições e métodos para alfavírus vivos atenuados. em determinadas modalidades, uma composição de vírus vivo atenuado inclui, mas sem se limitar, um ou mais alfavírus vivos atenuados e composições para reduzir a inativação e/ou degradação do alfavírus vivo atenuado. em outras modalidades, a composição de vírus vivo atenuado pode ser uma composição de vacina. em outras composições, ainda, uma composição de alfavírus vivo atenuado pode incluir um tampão de hepes. em outras modalidades, o tampão de hepes pode incluir, ainda, um carboidrato e gelatina e/ou um sal 1/1
BR112015023205A 2013-03-14 2014-03-13 composições e métodos para formulações de alfavírus vivo atenuado BR112015023205A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14
PCT/US2014/026570 WO2014151855A1 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Publications (1)

Publication Number Publication Date
BR112015023205A2 true BR112015023205A2 (pt) 2017-07-18

Family

ID=50489420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023205A BR112015023205A2 (pt) 2013-03-14 2014-03-13 composições e métodos para formulações de alfavírus vivo atenuado

Country Status (20)

Country Link
US (2) US10137186B2 (pt)
EP (2) EP2968515B1 (pt)
JP (3) JP6426695B2 (pt)
KR (1) KR20160003662A (pt)
CN (2) CN105377293B (pt)
AP (1) AP2015008733A0 (pt)
AU (2) AU2014236804B2 (pt)
BR (1) BR112015023205A2 (pt)
CA (1) CA2903711A1 (pt)
CR (1) CR20150553A (pt)
DO (1) DOP2015000226A (pt)
EC (1) ECSP20007842A (pt)
HK (1) HK1220358A1 (pt)
MX (2) MX361342B (pt)
MY (1) MY178476A (pt)
NZ (1) NZ631012A (pt)
PH (1) PH12015502115A1 (pt)
SG (3) SG11201507462QA (pt)
TW (2) TW201900192A (pt)
WO (1) WO2014151855A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507462QA (en) 2013-03-14 2015-10-29 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
US10632184B2 (en) * 2016-03-31 2020-04-28 Takeda Vaccines, Inc. Compositions and methods for stabilizing alphaviruses with improved formulations
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
CA3174826A1 (en) * 2021-01-19 2022-07-28 Katsuro HAGIWARA Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6458560B1 (en) * 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
IL141176A0 (en) * 1998-07-30 2002-02-10 Univ Johns Hopkins Med Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
WO2003049764A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
DK1701738T3 (en) 2003-12-17 2015-03-30 Wyeth Llc Process for preparing storage-stable RSV compositions
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
EP2086581B1 (en) * 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
SI2144998T1 (sl) 2007-04-06 2017-05-31 Takeda Vaccines, Inc. Postopki in sestavki za žive atenuirane viruse
CA2698392C (en) 2007-09-04 2019-12-03 Baoming Jiang Thermal inactivation of rotavirus
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
CA2910235C (en) 2008-01-24 2021-07-06 Scott C. Weaver Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
ES2481040T3 (es) 2008-12-09 2014-07-29 Coley Pharmaceutical Group, Inc. Oligonucleótidos inmunoestimulantes
EP2519539A4 (en) 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
SG11201507462QA (en) 2013-03-14 2015-10-29 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations

Also Published As

Publication number Publication date
JP2020193231A (ja) 2020-12-03
US20140271715A1 (en) 2014-09-18
AU2018236897A1 (en) 2018-10-18
TW201900192A (zh) 2019-01-01
WO2014151855A1 (en) 2014-09-25
TWI649087B (zh) 2019-02-01
JP6761015B2 (ja) 2020-09-23
CN111729077A (zh) 2020-10-02
CA2903711A1 (en) 2014-09-25
ECSP20007842A (es) 2020-09-30
EP3603667A1 (en) 2020-02-05
AU2018236897B2 (en) 2020-09-10
US10137186B2 (en) 2018-11-27
DOP2015000226A (es) 2016-02-29
AU2014236804A1 (en) 2015-10-01
JP2019031543A (ja) 2019-02-28
EP2968515B1 (en) 2019-05-08
CR20150553A (es) 2015-12-01
SG10201801459SA (en) 2018-03-28
JP2016513658A (ja) 2016-05-16
KR20160003662A (ko) 2016-01-11
PH12015502115B1 (en) 2016-01-25
MX2018014977A (es) 2022-06-27
SG10201909051QA (en) 2019-11-28
NZ631012A (en) 2017-08-25
EP2968515A1 (en) 2016-01-20
HK1220358A1 (zh) 2017-05-05
TW201513875A (zh) 2015-04-16
MX2015012894A (es) 2016-04-04
CN105377293A (zh) 2016-03-02
US20190134182A1 (en) 2019-05-09
CN105377293B (zh) 2020-07-17
US10806781B2 (en) 2020-10-20
AP2015008733A0 (en) 2015-09-30
MX361342B (es) 2018-12-04
AU2014236804B2 (en) 2018-12-13
PH12015502115A1 (en) 2016-01-25
JP6426695B2 (ja) 2018-11-21
SG11201507462QA (en) 2015-10-29
MY178476A (en) 2020-10-14

Similar Documents

Publication Publication Date Title
BR112018013104B8 (pt) Composição e método para crescimento de cabelos ou pelos
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112018005316A2 (pt) ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?
BR112015021352A2 (pt) composições antimicrobianas
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001547A1 (es) Composiciones para el cuidado oral
BR112016025331A2 (pt) composições antimicrobianas
BR112015017405A2 (pt) composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas
BR112019001299A2 (pt) composições e métodos para estabilizar flavivírus com formulações aprimoradas
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BRPI0809663B8 (pt) composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
BR112015005590A2 (pt) composição para tratamento de tecidos
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112018008781A8 (pt) agente antimicrobiano compreendendo xantohumol e o uso do mesmo em produtos alimentícios
BR112015028824A2 (pt) composição de tensoativo concentrada
BR112015027824A2 (pt) composições de vitamina e em pó
MX2016012112A (es) Feromona tranquilizadora para gatos.
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
BR112018009889A2 (pt) composição e métodos para redução de penalização de rendimento de milho sobre milho
DOP2018000211A (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
BR112015031901A2 (pt) composições e métodos para tratamento pós-colheita
MX2016011572A (es) Composiciones antimicrobianas de acido organico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: TAKEDA VACCINES, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2662 DE 11-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.